These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11271495)

  • 101. Application of proteomics in the search for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases inhibitor, bohemine.
    Kovarova H; Halada P; Man P; Dzubak P; Hajduch M
    Technol Cancer Res Treat; 2002 Aug; 1(4):247-56. PubMed ID: 12625783
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Protein fingerprints of anti-cancer effects of cyclin-dependent kinase inhibition: identification of candidate biomarkers using 2-D liquid phase separation coupled to mass spectrometry.
    Skalnikova H; Halada P; Dzubak P; Hajduch M; Kovarova H
    Technol Cancer Res Treat; 2005 Aug; 4(4):447-54. PubMed ID: 16029063
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity.
    Trávnícek Z; Krystof V; Sipl M
    J Inorg Biochem; 2006 Feb; 100(2):214-25. PubMed ID: 16386795
    [TBL] [Abstract][Full Text] [Related]  

  • 104. The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors.
    Korinkova G; Cwiertka K; Paprskarova M; Dzubak P; Hajduch M
    Neoplasma; 2010; 57(2):161-9. PubMed ID: 20099981
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs.
    Hajdúch M; Havlíèek L; Veselý J; Novotný R; Mihál V; Strnad M
    Adv Exp Med Biol; 1999; 457():341-53. PubMed ID: 10500810
    [TBL] [Abstract][Full Text] [Related]  

  • 106. In vitro evaluation of a novel 2,6,9-trisubstituted purine acting as a cyclin-dependent kinase inhibitor.
    Giocanti N; Sadri R; Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Favaudon V
    Ann N Y Acad Sci; 1999; 886():180-2. PubMed ID: 10667214
    [No Abstract]   [Full Text] [Related]  

  • 107. ATP-site directed inhibitors of cyclin-dependent kinases.
    Gray N; Détivaud L; Doerig C; Meijer L
    Curr Med Chem; 1999 Sep; 6(9):859-75. PubMed ID: 10495356
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine.
    Kovárová H; Hajdúch M; Korínková G; Halada P; Krupicková S; Gouldsworthy A; Zhelev N; Strnad M
    Electrophoresis; 2000 Nov; 21(17):3757-64. PubMed ID: 11271495
    [TBL] [Abstract][Full Text] [Related]  

  • 109.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 110.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 111.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 112.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 113.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 114.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 6.